Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study between MD-0901 formulations in ulcerative colitis remission
jRCT2031230024Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Single-arm trial of Salcrozine and mesalazine in autoimmune colitis, sponsored by Mochida Pharmaceutical Co., Ltd. Primary endpoint: Nonoccurrence of rectal bleeding. Started Apr 2023; status: completed.
02
Drugs
Salcrozinemesalazine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031230024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230024.